DYN RSI Chart
Last 7 days
0.1%
Last 30 days
-11.6%
Last 90 days
11.9%
Trailing 12 Months
126.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 4.2M | 5.9M | 7.2M | 7.6M |
2022 | 806.0K | 1.0M | 1.8M | 2.9M |
2021 | 190.0K | 376.0K | 560.0K | 742.0K |
2020 | 265.0K | 240.0K | 215.0K | 0 |
2019 | 0 | 0 | 0 | 290.0K |
2018 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 12, 2024 | farwell wildon | sold | -26,347 | 25.58 | -1,030 | chief medical officer |
Mar 11, 2024 | farwell wildon | sold | -40,734 | 25.7 | -1,585 | chief medical officer |
Mar 11, 2024 | high susanna gatti | sold | -58,904 | 25.7 | -2,292 | chief operating officer |
Mar 11, 2024 | scalzo richard william | sold | -67,541 | 25.2775 | -2,672 | svp, head of finance & admin. |
Mar 11, 2024 | brumm joshua t | sold | -1,704,140 | 25.6698 | -66,387 | ceo & president |
Mar 11, 2024 | beskrovnaya oxana | sold | -53,481 | 25.7 | -2,081 | chief scientific officer |
Mar 11, 2024 | brumm joshua t | acquired | 277,000 | 5.54 | 50,000 | ceo & president |
Mar 11, 2024 | mcneill jonathan | sold | -499,842 | 25.5008 | -19,601 | chief business officer |
Mar 11, 2024 | mcneill jonathan | acquired | 98,750 | 5.54 | 17,825 | chief business officer |
Mar 08, 2024 | scalzo richard william | sold | -2,261,470 | 26.2193 | -86,252 | svp, head of finance & admin. |
Which funds bought or sold DYN recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 24, 2024 | AlphaCentric Advisors LLC | new | - | 567,800 | 567,800 | 0.34% |
Apr 24, 2024 | Assenagon Asset Management S.A. | sold off | -100 | -3,812,360 | - | -% |
Apr 24, 2024 | DekaBank Deutsche Girozentrale | added | 50.00 | 1,184,000 | 1,710,000 | -% |
Apr 23, 2024 | AMALGAMATED BANK | reduced | -55.25 | -2,000 | 57,000 | -% |
Apr 23, 2024 | ARCADIA INVESTMENT MANAGEMENT CORP/MI | new | - | 889,317 | 889,317 | 0.16% |
Apr 23, 2024 | WETZEL INVESTMENT ADVISORS, INC. | new | - | 23,650 | 23,650 | 0.01% |
Apr 22, 2024 | Raymond James Financial Services Advisors, Inc. | new | - | 877,365 | 877,365 | -% |
Apr 22, 2024 | RAYMOND JAMES & ASSOCIATES | added | 95.34 | 3,646,460 | 4,796,860 | -% |
Apr 22, 2024 | Vivo Capital, LLC | added | 57.96 | 32,654,200 | 46,421,500 | 3.65% |
Apr 22, 2024 | MetLife Investment Management, LLC | unchanged | - | 99,529 | 305,009 | -% |
Unveiling Dyne Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Dyne Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 40.6B | 6.8B | -8.61 | 5.92 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.1B | 1.8B | -41.1 | 9.9 | ||||
BMRN | 15.5B | 2.4B | 92.47 | 6.41 | ||||
INCY | 11.5B | 3.7B | 19.23 | 3.11 | ||||
MID-CAP | ||||||||
APLS | 5.8B | 396.6M | -10.92 | 14.56 | ||||
BBIO | 4.3B | - | -6.55 | 60.35 | ||||
AXSM | 3.4B | 270.6M | -14.16 | 12.52 | ||||
ARWR | 2.7B | 240.7M | -9.12 | 12.18 | ||||
ACAD | 2.7B | 726.4M | -43.85 | 3.7 | ||||
SMALL-CAP | ||||||||
CPRX | 1.7B | 398.2M | 24.23 | 4.35 | ||||
NVAX | 552.8M | 983.7M | -1.01 | 0.56 | ||||
CRBP | 351.2M | 881.7K | -7.87 | 466.16 | ||||
INO | 236.5M | 4.9M | -1.75 | 48.6 | ||||
IBIO | 5.9M | 2.1M | -0.22 | 2.14 |
Dyne Therapeutics Inc News
Income Statement (Quarterly) | |||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2018Q4 |
Revenue | -20.0% | 1,751,500 | 2,189,000 | 2,207,000 | 1,493,000 | 1,342,500 | 903,000 | 441,000 | 230,000 | 182,000 | 184,000 | 210,000 | 166,000 | - | - | 24,000 | 67,000 | 110,000 | - |
Operating Expenses | 8.7% | 67,688,500 | 62,273,000 | 66,736,000 | 45,464,000 | 40,145,000 | 42,279,000 | 52,755,000 | 35,783,000 | 51,960,000 | 42,766,000 | 30,165,000 | 25,134,000 | 13,520,000 | 8,675,000 | 7,853,000 | - | 3,629,000 | - |
S&GA Expenses | 25.9% | 8,844,000 | 7,022,000 | 7,606,000 | 7,928,000 | 6,955,000 | 7,609,000 | 6,091,000 | 7,547,000 | 9,659,000 | 6,256,000 | 6,293,000 | 6,509,000 | 3,841,000 | 1,341,000 | 1,764,000 | - | 647,000 | - |
R&D Expenses | 6.5% | 58,844,500 | 55,251,000 | 59,130,000 | 37,536,000 | 33,190,000 | 34,670,000 | 46,664,000 | 28,236,000 | 42,301,000 | 36,510,000 | 23,872,000 | 18,625,000 | 9,679,000 | 7,334,000 | 6,089,000 | - | 2,982,000 | - |
EBITDA Margin | - | - | - | - | - | - | - | - | - | - | 140 | 122 | 180 | 200 | 1,637 | 818 | - | - | - |
EBT Margin | - | - | - | - | - | - | - | - | - | - | -960 | -832 | -1,233 | -1,372 | -11,208 | -5,604 | - | - | - |
Net Income | -10.7% | -66,638,000 | -60,210,000 | -64,902,000 | -44,187,000 | -38,827,000 | -41,385,000 | -52,304,000 | -35,583,000 | -51,786,000 | -42,582,000 | -29,955,000 | -24,968,000 | -13,920,000 | -8,982,000 | -7,886,000 | -5,403,500 | -5,871,000 | - |
Net Income Margin | -7.3% | -30.88 | -28.78 | -31.84 | -42.28 | -57.64 | -103 | -175 | -198 | -201 | -206 | -202 | -217 | - | - | - | - | - | - |
Free Cashflow | 30.9% | -35,088,000 | -50,769,000 | -55,892,000 | -47,138,000 | -29,711,000 | -43,691,000 | -31,170,000 | -52,140,000 | -30,058,000 | -27,833,000 | -46,888,000 | -18,402,000 | - | - | - | - | - | - |
Balance Sheet | |||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2018Q4 |
Assets | -19.6% | 165 | 205 | 251 | 289 | 306 | 300 | 340 | 388 | 426 | 467 | 467 | 492 | 353 | 381 | - | - | - | - |
Current Assets | -23.1% | 129 | 168 | 213 | 249 | 266 | 258 | 298 | 344 | 382 | 425 | 461 | 487 | 349 | 380 | - | - | 15.00 | 8.00 |
Cash Equivalents | -6.6% | 122 | 130 | 168 | 181 | 172 | 145 | 136 | 148 | 201 | 229 | 258 | 311 | 301 | 380 | - | - | 15.00 | 8.00 |
Net PPE | -6.5% | 5.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 5.00 | 6.00 | 5.00 | 3.00 | 3.00 | 2.00 | 2.00 | 1.00 | - | - | 1.00 | 0.00 |
Liabilities | 38.7% | 74.00 | 53.00 | 45.00 | 47.00 | 54.00 | 50.00 | 53.00 | 51.00 | 57.00 | 53.00 | 15.00 | 13.00 | 11.00 | 15.00 | 11.00 | 6.00 | 2.00 | 4.00 |
Current Liabilities | 72.1% | 51.00 | 30.00 | 20.00 | 22.00 | 28.00 | 23.00 | 26.00 | 23.00 | 29.00 | 23.00 | - | - | 11.00 | 5.00 | - | - | 2.00 | 1.00 |
Shareholder's Equity | -40.0% | 91.00 | 152 | 207 | 242 | 252 | 250 | 287 | 336 | 368 | 414 | 453 | 478 | 342 | 367 | - | 8.00 | 14.00 | - |
Retained Earnings | -11.8% | -632 | -565 | -505 | -440 | -396 | -357 | -316 | -264 | -228 | -176 | -134 | -104 | -79.18 | -50.53 | - | - | -19.75 | -4.89 |
Additional Paid-In Capital | 0.8% | 724 | 718 | 713 | 683 | 650 | 608 | 605 | 601 | 597 | 591 | 587 | 582 | 422 | 417 | - | - | 6.00 | 0.00 |
Shares Outstanding | 0.2% | 61.00 | 61.00 | 61.00 | 58.00 | 56.00 | 52.00 | 52.00 | 52.00 | 52.00 | 51.00 | 50.00 | 49.00 | - | - | - | - | - | - |
Float | - | - | - | 504 | - | - | - | 216 | - | - | - | - | - | - | - | 629 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2018Q4 |
Cashflow From Operations | 30.8% | -35,006 | -50,602 | -55,642 | -46,908 | -29,192 | -42,805 | -30,909 | -50,739 | -28,068 | -26,952 | -46,150 | -18,393 | -20,036 | -11,886 | -7,298 | -7,288 | - | - | - |
Share Based Compensation | 17.5% | 5,730 | 4,876 | 4,749 | 4,617 | 3,832 | 3,827 | 3,031 | 4,488 | 6,013 | 3,638 | 4,239 | 3,652 | 4,215 | 2,235 | 75.00 | 66.00 | - | - | - |
Cashflow From Investing | 104.3% | 26,196 | 12,821 | 17,232 | 27,062 | 19,237 | 51,658 | 18,443 | -2,136 | -235 | -2,848 | -6,434 | -128,375 | -45,223 | -156 | -71.00 | -211 | - | - | - |
Cashflow From Financing | -67.6% | 147 | 454 | 24,906 | 28,815 | 37,203 | 70.00 | 99.00 | 18.00 | 89.00 | 457 | 25.00 | 157,250 | -11,194 | 379,976 | - | 11,908 | - | - | - |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development | $ 210,762 | $ 142,760 |
General and administrative | 31,400 | 28,202 |
Total operating expenses | 242,162 | 170,962 |
Loss from operations | (242,162) | (170,962) |
Other (expense) income: | ||
Interest income | 7,641 | 2,917 |
Other income (expense), net | (1,416) | (54) |
Total other (expense) income, net | 6,225 | 2,863 |
Net loss | $ (235,937) | $ (168,099) |
Net loss per share, basic and diluted | $ (3.95) | $ (3.23) |
Net loss per share, basic and diluted | $ (3.95) | $ (3.23) |
Weighted average common shares outstanding, basic and diluted | 59,683,851 | 51,976,343 |
Weighted average common shares outstanding, basic and diluted | 59,683,851 | 51,976,343 |
Comprehensive loss: | ||
Net Income (Loss) | $ (235,937) | $ (168,099) |
Other comprehensive loss: | ||
Unrealized gains (losses) on marketable securities, net | 571 | (302) |
Comprehensive loss | $ (235,366) | $ (168,401) |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 121,626 | $ 172,147 |
Marketable securities | 1,474 | 83,865 |
Prepaid expenses and other current assets | 6,275 | 9,582 |
Total current assets | 129,375 | 265,594 |
Property and equipment, net | 4,780 | 5,945 |
Right-of-use assets | 28,612 | 32,467 |
Restricted cash | 2,315 | 2,319 |
Total assets | 165,082 | 306,325 |
Current liabilities: | ||
Accounts payable | 22,936 | 5,259 |
Accrued expenses and other current liabilities | 23,439 | 18,219 |
Lease liabilities | 4,720 | 4,610 |
Total current liabilities | 51,095 | 28,088 |
Lease liability, net of current portion | 22,695 | 25,873 |
Total liabilities | 73,790 | 53,961 |
Commitments and contingencies (Note 10) | ||
Stockholders’ equity | ||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2023 and 2022 | 0 | 0 |
Common stock, $0.0001 par value; 200,000,000 shares authorized at December 31, 2023 and 2022; 61,468,743 and 55,636,505 shares issued and outstanding at December 31, 2023 and 2022, respectively | 6 | 6 |
Additional paid-in capital | 723,796 | 649,502 |
Accumulated other comprehensive loss | 0 | (571) |
Accumulated deficit | (632,510) | (396,573) |
Total stockholders’ equity | 91,292 | 252,364 |
Total liabilities and stockholders’ equity | $ 165,082 | $ 306,325 |
 | Mr. Joshua T. Brumm |
---|---|
 | dyne-tx.com |
 | Biotechnology |
 | 134 |